Integrated approaches to lead optimization: Improving the therapeutic index

Predictive Toxicology in Drug Safety

Volumn , Issue , 2010, Pages 183-203

  Urban, Laszlo ^a   Wang, Jianling ^a   Bojanic, Dejan ^a   Ward, Susan ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927082469     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511779053.012     Document Type: Chapter

References (47)

1. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. JPham Toxicol Methods. 2000;44:235-249.
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711-716.
3. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. New Engl J Med. 1992;327:227-233.
4. Keating MT, Sanguinetti, MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell. 2001;104:569-580.
5. Jamieson C, Moir EM, Rankovic Z, et al. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. J Med Chem. 2006;49:5029-5046.
6. Pearlstein R Vaz R, Rampe D. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem. 2003;46:2017-2022.
7. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45.
8. Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov. 2007;6:636-649.
9. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6:881-890.
10. Bender A, Jenkins JL, Glick M, et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effect from chemical structure. Chem Med Chem. 2007;2:1-14.
11. Wang J, Urban L, Bojanic D. Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opin Drug Metab Toxicol. 2007;3:641-665.
12. Wang J. Comprehensive assessment of ADMET risks in drug discovery. Curr Pham Design, 2009;5(19):2195-2219.
13. Kerns EH, Di L. Physicochemical profiling: Overview of the screens. Drug Discov Today Technol. 2004;1:343-348.
14. Thomas VH, Bhattachar S, Hitchingham L, et al. The road map to oral bioavailability: An industrial perspective. Expert Opin Drug Metab Toxicol. 2006; 2:591-608.
15. Li AP. Building predictive ADMET models for early decisions in drug discovery. Drug Discov Today. 2001;6:357-366.
16. Ramot Y, Nyska A. Drug-induced thrombosis - Experimental, clinical, and mechanistic considerations. Toxicol Pathol. 2007;35:208-225.
17. Meyer CH, Schmidt JC, Rodrigues EB, et al. Risk of retinal vein occlusions in patients treated with rofecoxib (Vioxx). Ophthalmologica. 2005;219:243-247.
18. Zhu W, Zeng X, Zheng M, et al. The enigma of p2 adrenergic receptor Gi signaling in the heart. The good, the bad, and the ugly. Circ Res. 2005;97:507-509.
19. Shamovsky I, Connolly S, David L, et al. Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships. J Med Chem. 2008;51:1162-1178.
20. Obradovic T, Dobson G, Shingaki T, et al. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pham Res. 2007;24:318-327.
21. Faller B, Wang J, Zimmerlin A, et al. High-throughput in-vitro profiling assays: How useful for decision making? Exp Opin Drug Metab Toxicol. 2006;2:823-833.
22. Rubinstein AL. Zebrafish assays for drug toxicity screening. Expert Opin Drug Metab Toxicol. 2006;2:231-240.
23. Peterson RT, Nass R, Boyd WA, et al. Use of non-mammalian alternative models for neurotoxicological study. Neurotoxicology. 2008;29:546-555.
24. Whitebread S, Hamon J, Bojanic D, et al. In vitro safety pharmacology profiling: An essential tool for drug development. DrugDiscov Today. 2005;10:1421-1433.
25. Vaz RJ, Klabunde T. Eds. Antitargets: Prediction and Prevention of Drug Side Effects. Wiley-VCH, Weinheim; 2008.
26. Krejsa CM, et al. Predicting ADME properties and side effects: The BioPrint approach. Curr Opin Drug Discov Dev. 2003;6:470-480.
27. Zhang S, Zhou Z, Gong Q, et al. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res. 1999;84:989-998.
28. Giuliano KA, J ohnston PA, Gough A, et al. Systems cell biology based on highcontent screening. Methods Enzymol. 2006;414:601-619.
29. Cellumen. Cell Ciphr Toxicity Profiling. http://www.cellumen.com/solutions/cyto-toxicity-csb.php., accessed date: 07. 05. 2010.
30. Morelli JK, Buehrle M, Pognan F, et al. Validation of an in vitro screen for phospho-lipidosis using a high-content biology platform. Cell Biol Toxicol. 2006;22(1):15-27.
31. Hamon J, Whitebread S, Techer-Etienne V, et al. In vitro safety pharmacology profiling: What else beyond hERG? 2009; 1(4):645-665.
32. Ambit Biosciences. http://www.ambitbio.com. Accessed date: 07. 05. 2010.
33. Goldstein, DM, Gray GS, Zarrinkar PP. High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov. 2008;7:391-397.
34. Lu LY, Wood JL, Ye L, et al. Aurora A is essential for early embryonic development and tumor suppression. J Biol Chem. 2008;283:31785-31790.
35. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Hoboken, NJ: John Wiley & Sons, 2008.
36. Elangbam CS, Job LE, Zadrozny LM, et al. 5-hydroxytryptamine (5HT)-induced val-vulopathy: Compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats; Exp Toxicol Pathol. 2008;60(4-5):253-262.
37. Pharmapendium. https://www.pharmapendium.com.
38. GVK Biosciences. http://www.gvkbio.com. Accessed 08. 05. 2010.
39. Lhasa Ltd, DEREK. https://www.lhasalimited.org/index.php/derek/Accessed 08. 05. 2010.
40. Cheng A. In silico prediction of hepatotoxicity Curr Computer-Aided Drug Design. 2009;5:122-127.
41. Multicase Inc. Bioactive software. http://www.multicase.com. Accessed 09. 05. 2010.
42. Ekins S, ed. Computational Toxicology. Wiley-VCH, Hoboken NJ: 2007.
43. Ekins, S. Predicting undesirable drug interactions with promiscuous proteins in sil-ico. Drug Discov Today. 2004;9:276-285.
44. Azzaoui K, Hamon J, Faller B, et al. Modeling promiscuity based on; n vitro safety pharmacology profiling data Chem Med Chem. 2007; 2:874-880.
45. Whitebread S, Hamon J, Scheiber J, et al. Broad-scale in vitro pharmacology profiling to predict clinical adverse effects. Am. Drug Discov. 2008;1(7):1-5.
46. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. 2006;5:75-86.
47. Dieterle F, Marrer E, Suzuki E, et al. Monitoring kidney safety in drug development: Emerging technologies and their implications; Curr Opin Drug Discov Devel. 2008; 11:60-71.